Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-935 and midazolam pharmacokinetic interaction study in healthy adults
NL-OMON51575Active, not recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of izumerogant and midazolam in chronic inflammatory conditions, sponsored by Immunic Therapeutics. Primary endpoint: Effect of multiple doses of IMU-935 on midazolam pharmacokinetics. Started Jan 2022; status: active, not recruiting.
02
Drugs
izumerogantmidazolam
03
Conditions
chronic inflammatory conditions
Beyond the preview
Go deeper on NL-OMON51575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51575.